Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy

Clinical Autonomic Research

Volumn 13, Issue 1, 2003, Pages 51-53

  Sakakibara, Ryuji ^a   Uchiyama, Tomoyuki ^a   Asahina, Masato ^a   Yoshiyama, Mitsuharu ^a   Yamanishi, Tomonori ^b   Hattori, Takamichi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Amezinium metilsulfate; Multiple system atrophy (MSA); Postural hypotension; Sympathetic receptor agonist; Urinary retention

Indexed keywords

AMEZINIUM METILSULFATE;

ADULT; ARTICLE; BLOOD VESSEL WALL; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; RESIDUAL URINE; RISK; SHY DRAGER SYNDROME; URETHRA; URINE RETENTION;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PYRIDAZINES; RETROSPECTIVE STUDIES; SYMPATHOMIMETICS; URINARY RETENTION; URODYNAMICS;

EID: 0038369248     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10286-003-0034-5     Document Type: Article

References (13)

1. Bannister R, Mathias CJ (1999) Management of postural hypotension. In: Mathias CJ, Bannister R (eds) Autonomic Failure; a Textbook of Clinical Disorders of the Autonomic Nervous System. Fourth edition. Oxford University Press, Oxford, pp 342-356
2. Kita K, Hirayama K (1988) Treatment of neurogenic orthostatic hypotension with amezinium metilsulfate, a new indirect sympathomimetic drug. Neurology 38:1095-1099
3. Low PA, Bannister R (1997) Multiple system atrophy and pure autonomic failure. In: Low PA (ed) Clinical Autonomic Disorders, Second edition. Lippincott-Raven Publishers, Philadelphia, pp 555-575
4. Beck RO, Betts CD, Fowler CJ (1994) Genitourinary dysfunction in multiple system atrophy; clinical features and treatment in 62 cases. J Urol 151:1336-1341
5. Sakakibara R, Hattori T, Uchiyama T, Kita K, Asahina M, Suzuki A, Yamanishi T (1999) Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 67:1-5
6. Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, Egoshi K, Sekita N (2000) Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 79:191-195
7. Chapple CR (1995) α-Adrenergic blocking drugs in bladder outflow obstruction: what potential has α-adrenoceptor selectivity? Br J Urol 76 (Suppl 1):47-55
8. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo Jr RR (1995) International union of pharmacology X; recommendation for nomenclature of α1-adrenoceptors, consensus update. Pharmacol Rev 47:267-270
9. Schwinn DA (2000) Novel role for α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU International 86 (Suppl 2):11-22
10. Petersen T, Husted SE (1993) Prazosin treatment of neurological patients with lower urinary tract dysfunction. Int Urogynecol J 4:106-110
11. Nanninga JB, Kaplan P, Lal S (1977) Effect of phentolamine on perineal muscle EMG activity in paraplegia. Br J Urol 49:537-539
12. Perrigot M, Delauche-Cavallier MC, Amarenco G, Geffriaud C, Stalla-Bourdillon A, Costa P, DORALI Study Group (1996) Effect of intravenous alfzosin on urethral pressure in patients with neurogenic bladder dysfunction. Neurourol Urodynam 15:119-131
13. Kiesswetter H, Hennrich F, Englisch M (1983) Clinical and urodynamic assessment of pharmacologic therapy of stress incontinence. Urol Int 38:58-63